Acute myeloid leukemia of the elderly: recent progresses in therapy

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 高齢者急性骨髄性白血病：治療最前線
  • コウレイシャ キュウセイ コツズイセイ ハッケツビョウ : チリョウ サイゼンセン

Search this article

Abstract

<p>Therapeutic modalities for acute myeloid leukemia (AML) in elderly include intensive chemotherapy, less-intensive chemotherapy, and best supportive care. The choice of treatment is based on patients’ general physical condition, leukemic prognostic factors, preference of the patient/family, and the available social support. Findings of comprehensive geriatric assessment and comorbidities are considered while selecting therapeutic modalities. AML score may suggest the appropriateness of the use of intensive chemotherapy. When intensive chemotherapy is tolerable, enocitabine or cytarabine + daunorubicin is used as remission induction chemotherapy. Consolidation chemotherapy comprising three courses of cytarabine-based regimens is administered after complete remission. When intensive chemotherapy is not tolerable, low-dose cytarabine is used. CPX351, a novel antileukemic agent, is a liposomal formulation of asynergistic 5 : 1 molar ratio of cytarabine and daunorubicin. In a randomized phase 2 trial in older patients with AML, CPX351 showed better response rate and survival than cyarabine + daunorubicin regimen.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 59 (6), 735-740, 2018

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top